Kevin Jon Balbi

Kevin Jon Balbi

Auto-generated profile, based on publicly available information

Kevin Jon Balbi

Sarah Cannon Molecular Diagnostics, HCA International Ltd, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
INIsabella Caroline Chiara Niesner
Isabella Caroline Chiara Niesner
KBKevin Jon Balbi
Kevin Jon Balbi
BPBenjamin Poskitt
Benjamin Poskitt
CGCarolina Gemma
Carolina Gemma
JLJosep Linares
Josep Linares
DMDavid Allan Moore
David Allan Moore
Kirsten rat sarcoma viral oncogene (KRAS) is a frequently mutated oncogene in lung cancer, now amenable to targeted therapy with allele-specific G12C inhibitors. Non-small cell lung cancer (NSCLC) driver mutations show geographical variability and therefore the KRAS mutation breakdown, co-occurring oncogenic mutation rate and associated PD-L1 expression were studied in a large UK cohort. We interrogated archival clinical next-generation sequencing (NGS) data over 5 years. 3283 NSCLC samples were included, referred from 38 centres over 4 years. Somatic mutation hotspots in cancer-associated genes were analysed using ampliseq/ion-torrent based NGS assays. In a subset of the cohort, PD-L1 scores were also collated. 1118 KRAS variants were detected. Class I mutations occurred most frequently (86.94%), with KRAS G12C, G12V and G12D being most prevalent. Class II (7.96%), III (4.65%) and IV (0.45%) mutations were also detected and mutations in PIK3CA and BRAF were the most frequently observed co-mutations. No significant difference in PD-L1 expression was found between KRAS wild-type and mutant tumours.

24 June 2021 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
DMDavid Allan Moore
David Allan Moore
KBKevin Jon Balbi
Kevin Jon Balbi
BPBenjamin Poskitt
Benjamin Poskitt
PBPhilip Bennett
Philip Bennett
Novel therapeutic agents for patients with EGFR exon 20 insertions are currently in trials, and as such, determining the frequency and diversity of exon 20 mutations in the NSCLC population may be highly relevant to future clinical practice.3 Since data from most qPCR-based EGFR tests are unlikely to identify and will not classify the full spectrum of exon …